These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

761 related items for PubMed ID: 27817164

  • 1. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P, Sikirica V, Chen YJ, Curtice TG, Makin C.
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [Abstract] [Full Text] [Related]

  • 2. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y, Yang L, Stein MA, Cao Q, Wang Y.
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [Abstract] [Full Text] [Related]

  • 3. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [Abstract] [Full Text] [Related]

  • 4. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
    Molife C, Haynes VS, Nyhuis A, Faries DE, Gelwicks S, Kelsey DK, Alatorre CI.
    Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
    [Abstract] [Full Text] [Related]

  • 5. Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.
    Štuhec M, Locatelli I, Švab V.
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):254-9. PubMed ID: 25803789
    [Abstract] [Full Text] [Related]

  • 6. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B, Karakaya E, Oztop DB.
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [Abstract] [Full Text] [Related]

  • 7. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
    Shyu YC, Lee SY, Yuan SS, Yang CJ, Yang KC, Lee TL, Wang LJ.
    Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
    [Abstract] [Full Text] [Related]

  • 8. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
    Hong J, Dilla T, Arellano J.
    BMC Psychiatry; 2009 Apr 14; 9():15. PubMed ID: 19366449
    [Abstract] [Full Text] [Related]

  • 9. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.
    Curr Med Res Opin; 2014 Aug 14; 30(8):1673-85. PubMed ID: 24627974
    [Abstract] [Full Text] [Related]

  • 10. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
    Liu Q, Zhang H, Fang Q, Qin L.
    J Clin Exp Neuropsychol; 2017 Nov 14; 39(9):854-865. PubMed ID: 28052720
    [Abstract] [Full Text] [Related]

  • 11. Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
    Deng L, Zhou P, Zhu L, Zhang Y, Yang T, Zhao Q, Chen J, Li T, Cheng Q, Chen L.
    Pharmacol Biochem Behav; 2021 Sep 14; 208():173225. PubMed ID: 34217783
    [Abstract] [Full Text] [Related]

  • 12. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.
    Expert Rev Neurother; 2011 Apr 14; 11(4):499-508. PubMed ID: 21469923
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Switch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient Records.
    Warrer P, Thomsen PH, Dalsgaard S, Hansen EH, Aagaard L, Wallach Kildemoes H, Rasmussen HB.
    J Child Adolesc Psychopharmacol; 2016 May 14; 26(4):354-61. PubMed ID: 26891424
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.
    J Manag Care Pharm; 2012 May 14; 18(9):676-89. PubMed ID: 23206211
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Methylphenidate and Atomoxetine in Medication-Naive Children with Attention-Deficit Hyperactivity Disorder in a Real-World Setting.
    Zhang Y, Yin L, You C, Liu C, Dong P, Xu X, Zhang K.
    Drugs R D; 2024 Mar 14; 24(1):29-39. PubMed ID: 37982991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.